Risk of ipsilateral breast tumor recurrence in patients treated with tamoxifen or anastrozole following breast-conserving surgery with or without radiotherapy
Anticancer Research, 01/31/2011
ISHITOBI M et al.
– Caution is needed when RT is omitted for patients undergoing breast-conserving surgery and receiving Ana for adjuvant treatment.
292 breast cancer patients who had undergone breast-conserving surgery and been treated with Tam or Ana, with or without RT retrospectively analyzed
Ipsilateral breast tumor recurrence (IBTR)-free survival rates compared according to treatment drug and RT
In Tam group, IBTR-free survival rates did not significantly differ according to use or absence of RT (p=0.08), whereas in Ana group, a significant difference (5-year IBTR-free survival rate, 98.8% in the RT group vs. 65.7% in the no RT group, p<0.0001) found
Multivariate analysis showed that RT use was an independent prognostic factor for IBTR-free survival (p=0.01) among patients treated with Ana
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.